Tags : KN026

Alphamab Oncology Signs an Agreement with Sanofi for KN026

Shots: Sanofi to get an exclusivity period for negotiating the in-licensing of KN026 with achievement of certain clinical milestones. The companies have initiated the enrollment for patients in the study which will evaluate KN026 +Taxotere (Docetaxel) in patients with HER2+ breast cancer The focus of the agreement is to advance clinical studies to evaluate KN026 […]Read More